Dr Preety Jain, Dr Vikas Pal, Dr Manish Verma, Dr Pranjil Mandloi, Dr Anshika Gupta, Dr Garima Ulkey, DR Priyanka Ahirwar, DR Prabhakar Gupta


cancer is the third most common cancer in women
worldwide with global estimates of 529,800 new cases and
1 275,100 deaths in 2011 . Developing countries have higher
incidence of cervical cancer cases and deaths occur because
of lack of effective screening procedures, socio- economic
2 challenge, pattern of healthcare delivery and social factors .
Cervical cancer is the second most common cancer in India in
women accounting for 22.86% of all cancer cases in women
3 and 12% of all cancer cases in both men and women . Rural
women are at higher risk of developing cervical cancer as
4 compared to their urban counterparts . Cervical cancer is the
third largest cause of cancer mortality in India accounting for
5 nearly 10% of all cancer related deaths in the country .

Full Text:



] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:1–22.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N Engl J Med. 1999;340(1144):53


Karthigeyan, K.; Cervical cancer in India and HPV vaccination.;2012; Indian J Med Paediatr Oncol.; 33(1): 7–12

World Health Organisation. The Global Burden of Disease: 2004 Update Geneva, WHO, 2009b.

Rotman M, Pajak TF, Choi K, Clery M, Marcial V, Grigsby PW, Cooper J, John M. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: ten-year treatment results of RTOG 79-20. Jama. 1995 Aug 2;274(5):387-93.

Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology. 2007 Jul 1;25(19):2804-10.

Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. Gynecologic oncology. 2003 Jun 30;89(3):499-503

Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17(5):1339–48.

Eifel PJ, Winter K, Morris M. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of Radiation Therapy Oncology Group trial (RTOG) 90–01. J Clin Oncol 2004;22(5): 872–80.

Peters III WA, Liu PY, Barrett II RJ, Gordon Jr W, Stock RJ, Berek JS, et al. Cisplatin, 5- fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical


  • There are currently no refbacks.